Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • l40characters l40characters Jan 22, 2014 9:59 AM Flag

    Podhaler tobi pitch= will dwarf Arikace in worldwide sales for Cys fibrosis.

    The pitch is about the podhaler not Insmed price or non-tuberculous mycobacterial . Arikace will be a weak competitor in the Cys Fibrosis market. Europe has the podhaler in the recommended first tier. In 2 years when Arikace finally {if} gets to market it will be just another entry.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • michael_coen@ymail.com michael_coen Jan 22, 2014 10:21 AM Flag

      well guess what:
      [1] many of the podhaler users are irritated by the DRY powder (they can't take it / makes them cough too much, and the dry powder does not penetrate deep into the lungs;
      [2] the exact same Pari base until is installed in most EU CF patients' homes already (thanks to Cayston for that); just pop in the Arikace nebulizer and off you go... once/day job done.

 
INSM
21.09-0.11(-0.52%)May 4 4:00 PMEDT